| Year |
Citation |
Score |
| 2023 |
Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, Pizzato E, Birebent R, Mbogning Fonkou MD, Zoppi S, Reni A, ... ... Gervois N, et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science (New York, N.Y.). 380: eabo2296. PMID 37289890 DOI: 10.1126/science.abo2296 |
0.329 |
|
| 2021 |
Vaurs J, Douchin G, Echasserieau K, Oger R, Jouand N, Fortun A, Hesnard L, Croyal M, Pecorari F, Gervois N, Bernardeau K. A novel and efficient approach to high-throughput production of HLA-E/peptide monomer for T-cell epitope screening. Scientific Reports. 11: 17234. PMID 34446788 DOI: 10.1038/s41598-021-96560-9 |
0.39 |
|
| 2021 |
Denis Musquer M, Jouand N, Pere M, Lamer JE, Bézieau S, Matysiak T, Faroux R, Caroli Bosc FX, Rousselet MC, Leclair F, Mosnier JF, Toquet C, Gervois N, Bossard C. High-Density of FcγRIIIA (CD16) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis. Frontiers in Oncology. 11: 684478. PMID 34211852 DOI: 10.3389/fonc.2021.684478 |
0.437 |
|
| 2021 |
Mutala LB, Deleine C, Karakachoff M, Dansette D, Ducoin K, Oger R, Rousseau O, Podevin J, Duchalais E, Fourquier P, Thomas WEA, Gourraud PA, Bennouna J, Brochier C, Gervois N, et al. The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer. Cancers. 13. PMID 33430344 DOI: 10.3390/cancers13020189 |
0.34 |
|
| 2020 |
Parrot T, Oger R, Allard M, Desfrançois J, Raingeard de la Blétière D, Coutolleau A, Preisser L, Khammari A, Dréno B, Delneste Y, Guardiola P, Fradin D, Gervois N. Transcriptomic features of tumour-infiltrating CD4CD8 double positive αβ T cells in melanoma. Scientific Reports. 10: 5900. PMID 32246006 DOI: 10.1038/s41598-020-62664-x |
0.752 |
|
| 2019 |
Samimi M, Benlalam H, Aumond P, Gaboriaud P, Fradin D, Kervarrec T, Florenceau L, Vignard V, Blom A, Touzé A, Gervois N, Labarriere N. Viral and tumor antigen-specific CD8 T-cell responses in Merkel cell carcinoma. Cellular Immunology. 344: 103961. PMID 31472938 DOI: 10.1016/j.cellimm.2019.103961 |
0.515 |
|
| 2019 |
Eugène J, Jouand N, Ducoin K, Dansette D, Oger R, Deleine C, Leveque E, Meurette G, Podevin J, Matysiak T, Bennouna J, Bezieau S, Volteau C, Thomas WEA, Chetritt J, ... ... Gervois N, et al. The inhibitory receptor CD94/NKG2A on CD8 tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 31409873 DOI: 10.1038/S41379-019-0322-9 |
0.466 |
|
| 2018 |
Jouand N, Bressollette-Bodin C, Gérard N, Giral M, Guérif P, Rodallec A, Oger R, Parrot T, Allard M, Cesbron-Gautier A, Gervois N, Charreau B. HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition. Plos Pathogens. 14: e1007041. PMID 29709038 DOI: 10.1371/journal.ppat.1007041 |
0.761 |
|
| 2018 |
Bilonda L, Dansette D, Deleine C, Oger R, Jouand N, Podevin J, Fourquier P, Thibaudeau E, Chetritt J, Mosnier J, Bossard C, Gervois N, Jarry A. Abstract 4061: The inflammasome of tumor cells modulates the biology of tumor-infiltrating T lymphocytes in colorectal cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2018-4061 |
0.462 |
|
| 2017 |
Dugast E, David G, Oger R, Danger R, Judor JP, Gagne K, Chesneau M, Degauque N, Paul P, Picard C, Guerif P, Conchon S, Giral M, Gervois N, Retière C, et al. Broad Impairment of Natural Killer Cells from Operationally Tolerant Kidney Transplanted Patients. Frontiers in Immunology. 8: 1721. PMID 29312288 DOI: 10.3389/fimmu.2017.01721 |
0.33 |
|
| 2017 |
Bossard C, Dansette D, Ouairy A, Jouand N, Oger R, Bou-Hanna C, Laboisse C, Mosnier J, Gervois N, Jarry A. Role of the inflammasome of tumor cells in modulating the biology of Tumor Infiltrating T lymphocytes (TILs) in colorectal cancer. Journal of Clinical Oncology. 35: 640-640. DOI: 10.1200/Jco.2017.35.4_Suppl.640 |
0.527 |
|
| 2017 |
Bossard C, Eugene J, Jouand N, Dansette D, Leveque E, Podevin J, Matysiak T, Bezieau S, Chetritt J, Kerdraon O, Fourquier P, Thibaudeau E, Mosnier J, Jarry A, Gervois N. Intraepithelial CD94+ tumor-infiltrating lymphocytes in a context of HLA-E overexpression as a new immune checkpoint to predict prognosis in colorectal carcinomas. Journal of Clinical Oncology. 35: e14592-e14592. DOI: 10.1200/Jco.2017.35.15_Suppl.E14592 |
0.529 |
|
| 2016 |
Parrot T, Oger R, Benlalam H, Raingeard de la Blétière D, Jouand N, Coutolleau A, Preisser L, Khammari A, Dréno B, Guardiola P, Delneste Y, Labarrière N, Gervois N. CD40L confers helper functions to human intra-melanoma class-I-restricted CD4(+)CD8(+) double positive T cells. Oncoimmunology. 5: e1250991. PMID 28123891 DOI: 10.1080/2162402X.2016.1250991 |
0.518 |
|
| 2016 |
Parrot T, Allard M, Oger R, Benlalam H, Raingeard de la Blétière D, Coutolleau A, Preisser L, Desfrançois J, Khammari A, Dréno B, Labarrière N, Delneste Y, Guardiola P, Gervois N. IL-9 promotes the survival and function of human melanoma - infiltrating CD4(+) CD8(+) double-positive T cells. European Journal of Immunology. PMID 27094152 DOI: 10.1002/Eji.201546061 |
0.74 |
|
| 2014 |
Allard M, Oger R, Benlalam H, Florenceau L, Echasserieau K, Bernardeau K, Labarrière N, Lang F, Gervois N. Soluble HLA-I/peptide monomers mediate antigen-specific CD8 T cell activation through passive peptide exchange with cell-bound HLA-I molecules Journal of Immunology. 192: 5090-5097. PMID 24752447 DOI: 10.4049/Jimmunol.1303226 |
0.755 |
|
| 2012 |
Allard M, Tonnerre P, Nedellec S, Oger R, Morice A, Guilloux Y, Houssaint E, Charreau B, Gervois N. HLA-E-Restricted Cross-Recognition of Allogeneic Endothelial Cells by CMV-Associated CD8 T Cells: A Potential Risk Factor following Transplantation Plos One. 7. PMID 23226431 DOI: 10.1371/Journal.Pone.0050951 |
0.761 |
|
| 2012 |
Jotereau F, Gervois N, Labarrière N. Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility? Targeted Oncology. 7: 3-14. PMID 22350487 DOI: 10.1007/S11523-012-0207-Z |
0.56 |
|
| 2011 |
Allard M, Oger R, Vignard V, Percier JM, Fregni G, Périer A, Caignard A, Charreau B, Bernardeau K, Khammari A, Dréno B, Gervois N. Serum soluble HLA-E in Melanoma: A new potential immune-related marker in cancer Plos One. 6. PMID 21712991 DOI: 10.1371/Journal.Pone.0021118 |
0.716 |
|
| 2011 |
Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene. 30: 2622-32. PMID 21258414 DOI: 10.1038/Onc.2010.638 |
0.729 |
|
| 2011 |
Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, Gervois N, Allard M, Bercovici N, Avril MF, Caignard A. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2628-37. PMID 21224372 DOI: 10.1158/1078-0432.Ccr-10-2084 |
0.726 |
|
| 2011 |
Sarrabayrouse G, Corvaisier M, Ouisse LH, Bossard C, Le Mével B, Potiron L, Meurette G, Gervois N, Jotereau F. Tumor-reactive CD4+ CD8αβ+ CD103+ αβT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers. International Journal of Cancer. 128: 2923-32. PMID 20824715 DOI: 10.1002/Ijc.25640 |
0.567 |
|
| 2010 |
Douat-Casassus C, Borbulevych O, Tarbe M, Gervois N, Jotereau F, Baker BM, Quideau S. Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1(26(27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of T cell recognition. Journal of Medicinal Chemistry. 53: 7061-6. PMID 20806940 DOI: 10.1021/Jm100683P |
0.478 |
|
| 2010 |
Desfrançois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A, Dréno B, Jotereau F, Gervois N. Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas. Plos One. 5: e8437. PMID 20052413 DOI: 10.1371/Journal.Pone.0008437 |
0.471 |
|
| 2009 |
Desfrançois J, Derré L, Corvaisier M, Le Mével B, Catros V, Jotereau F, Gervois N. Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions. International Journal of Cancer. 125: 374-80. PMID 19358272 DOI: 10.1002/Ijc.24366 |
0.544 |
|
| 2008 |
Labarrière N, Gervois N, Bonnin A, Bouquié R, Jotereau F, Lang F. PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting Cancer Immunology, Immunotherapy. 57: 185-195. PMID 17646986 DOI: 10.1007/S00262-007-0361-9 |
0.555 |
|
| 2007 |
Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Blétière D, Loirand G, Pacaud P. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. Journal of Immunology (Baltimore, Md. : 1950). 179: 901-9. PMID 17617581 DOI: 10.4049/Jimmunol.179.2.901 |
0.332 |
|
| 2007 |
Douat-Casassus C, Marchand-Geneste N, Diez E, Gervois N, Jotereau F, Quideau S. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. Journal of Medicinal Chemistry. 50: 1598-609. PMID 17328535 DOI: 10.1021/Jm0613368 |
0.542 |
|
| 2006 |
Derré L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, Jotereau F, Gervois N. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. Journal of Immunology (Baltimore, Md. : 1950). 177: 3100-7. PMID 16920947 DOI: 10.4049/Jimmunol.177.5.3100 |
0.545 |
|
| 2006 |
Douat-Casassus C, Marchand-Geneste N, Diez E, Aznar C, Picard P, Geoffre S, Huet A, Bourguet-Kondracki ML, Gervois N, Jotereau F, Quideau S. Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological evaluation studies. Molecular Biosystems. 2: 240-9. PMID 16880942 DOI: 10.1039/B518044A |
0.54 |
|
| 2003 |
Jotereau F, Labarriere N, Gervois N, Pandolfino MC, Dreno B. [Passive immunotherapy of melanoma]. Bulletin Du Cancer. 90: 583-6. PMID 12957798 |
0.414 |
|
| 2003 |
Jotereau F, Labarrière N, Gervois N, Pandolfino MC, Dreno B. [Adoptive immunotherapy in solid tumors: new hope]. Medecine Sciences : M/S. 19: 268-70. PMID 12836404 DOI: 10.1051/Medsci/2003193268 |
0.349 |
|
| 2002 |
Trautmann L, Labarrière N, Jotereau F, Karanikas V, Gervois N, Connerotte T, Coulie P, Bonneville M. Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. European Journal of Immunology. 32: 3181-90. PMID 12555663 DOI: 10.1002/1521-4141(200211)32:11<3181::Aid-Immu3181>3.0.Co;2-2 |
0.436 |
|
| 2002 |
Labarrière N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dréno B, Jotereau F. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunology, Immunotherapy : Cii. 51: 532-8. PMID 12384804 DOI: 10.1007/S00262-002-0313-3 |
0.369 |
|
| 2002 |
Labarrière N, Bretaudeau L, Gervois N, Bodinier M, Bougras G, Diez E, Lang F, Gregoire M, Jotereau F. Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. International Journal of Cancer. Journal International Du Cancer. 101: 280-6. PMID 12209980 DOI: 10.1002/Ijc.10605 |
0.494 |
|
| 2002 |
Derre L, Corvaisier M, Pandolfino MC, Diez E, Jotereau F, Gervois N. Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 168: 4864-70. PMID 11994435 DOI: 10.4049/Jimmunol.168.10.4864 |
0.529 |
|
| 1999 |
Valmori D, Fonteneau J, Valitutti S, Gervois N, Dunbar R, Liénard D, Rimoldi D, Cerundolo V, Jotereau F, Cerottini J, Speiser DE, Romero P. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues International Immunology. 11: 1971-1980. PMID 10590263 DOI: 10.1093/Intimm/11.12.1971 |
0.595 |
|
| 1998 |
Le Dréan E, Vély F, Olcese L, Cambiaggi A, Guia S, Krystal G, Gervois N, Moretta A, Jotereau F, Vivier E. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. European Journal of Immunology. 28: 264-76. PMID 9485206 DOI: 10.1002/(Sici)1521-4141(199801)28:01<264::Aid-Immu264>3.0.Co;2-O |
0.581 |
|
| 1997 |
Toujas L, Delcros JG, Diez E, Gervois N, Semana G, Corradin G, Jotereau F. Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides. Immunology. 91: 635-42. PMID 9378506 DOI: 10.1046/J.1365-2567.1997.00287.X |
0.556 |
|
| 1996 |
Gervois N, Guilloux Y, Diez E, Jotereau F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. The Journal of Experimental Medicine. 183: 2403-7. PMID 8642353 DOI: 10.1084/Jem.183.5.2403 |
0.577 |
|
| 1995 |
Viret C, Gervois N, Guilloux Y, Le Dréan E, Diez E, Jotereau F. T cell activation by antigens on human melanoma cells--co-stimulation by B7-1 is neither sufficient nor necessary to stimulate IL-2 secretion by melanoma-specific T cell clones in vitro. International Immunology. 7: 1535-43. PMID 8562498 DOI: 10.1093/Intimm/7.10.1535 |
0.536 |
|
| 1995 |
Le Dréan E, Gervois N, Diez E, Semana G, Dreno B, Jotereau F. HLA class II-restricted recognition of common tumor epitopes on human melanoma cells by CD4+ melanoma-infiltrating lymphocytes. European Journal of Immunology. 25: 2732-6. PMID 7589064 DOI: 10.1002/Eji.1830251003 |
0.601 |
|
| 1994 |
Guilloux Y, Viret C, Gervois N, Le Dréan E, Pandolfino MC, Diez E, Jotereau F. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. European Journal of Immunology. 24: 1966-73. PMID 7522155 DOI: 10.1002/Eji.1830240905 |
0.547 |
|
| 1992 |
Pandolfino MC, Viret C, Gervois N, Guilloux Y, Davodeau F, Diez E, Jotereau F. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes. European Journal of Immunology. 22: 1795-802. PMID 1623924 DOI: 10.1002/Eji.1830220719 |
0.58 |
|
| 1991 |
Dellabona P, Wei BY, Gervois N, Benoist C, Mathis D. A single amino acid substitution in the Ak molecule fortuitously provokes an alloresponse. European Journal of Immunology. 21: 209-13. PMID 1846817 DOI: 10.1002/Eji.1830210131 |
0.421 |
|
| 1990 |
Gervois N, Heuze F, Diez E, Jotereau F. High proliferative capacity and specific antiautologous melanoma cytotoxicity of a human T-lymphocyte clone derived from tumor-infiltrating lymphocytes. Human Immunology. 28: 112-8. PMID 2141008 DOI: 10.1016/0198-8859(90)90006-B |
0.602 |
|
| 1990 |
Gervois N, Heuze F, Diez E, Jotereau F. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. European Journal of Immunology. 20: 825-31. PMID 1971794 DOI: 10.1002/Eji.1830200417 |
0.557 |
|
| Show low-probability matches. |